C3 Jian raises $30m to fund Phase I trials for tooth decay drug
This article was originally published in Scrip
In an incisive, oral health drug developer C3 Jian Inc. garnered $30 million in its third round of equity financing to fund human clinical trials for its lead candidate C16G2, a peptide drug targeting tooth decay.
You may also be interested in...
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.
The $80m financing will support a Phase III myelofibrosis study for the LSD1 inhibitor and earlier-stage programs, but additional late-stage studies will require an initial public offering, likely next year.